Therapy Response Correlation with Tumor Radio-Sensitivity for Non-Hodgkin's Lymphoma Treated with 131I Tositumomab

被引：0
|
作者：
Roberson, P. L. [1 ]
Wilderman, S. J. [1 ]
Avram, A. M. [1 ]
Kaminski, M. S. [1 ]
Schipper, M. J. [1 ]
Dewaraja, Y. K. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P0125
引用
收藏
页码：S336 / S336
页数：1
相关论文
共 50 条
  • [31] Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-hodgkin lymphoma: Nursing implications
    Estes, JM
    Clapp, KJ
    ONCOLOGY NURSING FORUM, 2004, 31 (06) : 1119 - 1126
  • [32] A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with >25% bone marrow involvement.
    Mones, J
    Coleman, M
    Kostakoglu, L
    Fiore, JM
    Muss, D
    Furman, R
    Stewart, P
    Kroll, S
    Goldsmith, SJ
    Leonard, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 576S - 576S
  • [33] Bexxar® (tositumomab and iodine I 131 tositumomab) is well tolerated and efficacious in heavily pretreated patients with non-Hodgkin's lymphoma (NHL) and mild thrombocytopenia.
    Goldsmith, SJ
    Kostakoglu, L
    Wahl, R
    Alavi, A
    Divgi, C
    Hankins, J
    Zelenetz, A
    Kaminski, M
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 33P - 34P
  • [34] Dosimetry optimizes tumor dose & enhances safety in non-hodgkins lymphoma patients [PTS] treated with 131I tositumomab [Bexxar™].
    Goldsmith, SJ
    Kaminski, M
    Wahl, R
    Vose, J
    Zelenetz, A
    Kroll, S
    Clapp, K
    Leonard, JL
    Presbyterian, NY
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 311P - 311P
  • [35] Comparison of 131I-Tositumomab (Bexxar®) and 90Y-Ibritumomab (Zevalin®) therapy of refractory/relapsed non-Hodgkin lymphoma
    Iagaru, A.
    Zhu, H.
    Mari, C.
    Knox, S. J.
    Ganjoo, K.
    Goris, M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S168 - S168
  • [36] Low-dose hyper-radiosensitivity model for 131I radioimmunotherapy of non-Hodgkin's lymphoma
    Roberson, Peter
    Wilderman, Scott
    Avram, Anca
    Kaminski, Mark
    Dewaraja, Yuni
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [37] Re-treatment with Tositumomab and Iodine I131 Tositumomab (the BEXXAR® therapeutic regimen) in patients with non-Hodgkin's lymphoma (NHL) with a previous response to the BEXXAR therapeutic regimen.
    Kaminski, MS
    Knox, SJ
    Radford, J
    Gregory, SA
    Leonard, JP
    BLOOD, 2003, 102 (11) : 407A - 407A
  • [38] Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL)
    Flowers, C. R.
    Sambrook, J. C.
    Briggs, A.
    Osenenko, K.
    Wang, H.
    Dalal, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Tositumomab and iodine I 131 tositumomab: Efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin's lymphoma (NHL).
    Kaminski, MS
    Coleman, M
    Link, BK
    Wahl, RL
    Goldsmith, SJ
    Kostakoglu, L
    Leonard, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
  • [40] Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology.
    Vose, JM
    Zelenetz, AD
    Rohatiner, A
    Knox, S
    Stagg, R
    Kroll, S
    Tidmarsh, G
    Kaminski, MS
    BLOOD, 1999, 94 (10) : 89A - 89A
12345